Corona Remedies IPO 2025 — Price Band, Dates, Lot Size, Financials & Review

Corona Remedies Ltd., established in 2004, is a pharma company with strong presence across women’s healthcare, cardiology, pain management, urology and multispecialty segments. With 71 brands, 2,671 medical reps and strong distribution across 22 states, it ranks among the fastest-growing Indian pharma companies. It operates two modern manufacturing facilities with a total capacity of 1,285+ million units annually.

Corona Remedies IPO

BSE & NSE — Book-built Offer-for-Sale Issue
UPCOMING
IPO Window
Dec 8 — Dec 10, 2025
Listing Date
Dec 15, 2025
Price Band
₹1008 — ₹1062
Lot Size
14 shares (Retail min: 1 lot)
Issue Size
₹655.37 Cr (OFS only)
Lead Manager
JM Financial Ltd.
Issue Terms
Face Value₹10 per share
Issue TypeBook-built Offer for Sale
Total Shares Offered61,71,101 shares
Employee Discount₹54 per share
RegistrarBigshare Services Pvt. Ltd.
ListingBSE, NSE
Reservation
CategoryAllocation
QIBNot less than 50%
RetailNot more than 35%
NII (HNI)Not more than 15%

Employee category eligible for discount & combined bidding rules as per RHP.

IPO Timeline (Tentative)
OpenDec 8, 2025
CloseDec 10, 2025
AllotmentDec 11, 2025
RefundsDec 12, 2025
Demat CreditDec 12, 2025
ListingDec 15, 2025
Lot Size & Investment
CategoryLotsSharesAmount (₹1062)
Retail Min114₹14,868
Retail Max13182₹1,93,284
S-HNI Min14196₹2,08,152
B-HNI Min68952₹10,11,024
About Corona Remedies Ltd.

Corona Remedies Ltd., established in 2004, is a pharma company with strong presence across women’s healthcare, cardiology, pain management, urology and multispecialty segments. With 71 brands, 2,671 medical reps and strong distribution across 22 states, it ranks among the fastest-growing Indian pharma companies. It operates two modern manufacturing facilities with a total capacity of 1,285+ million units annually.

Financial Snapshot
Financials (₹ crore)
Period202520242023
Revenue1202.351020.93891.10
PAT149.4390.5084.93
EBITDA245.91161.19135.03
Net Worth606.34480.41408.52
Key Metrics
ROE27.50%
ROCE41.32%
P/E35.15x (post)
EPS₹30.21 (post)

Financials restated per RHP.

Contact & Registrar

Corona Remedies Ltd.
CORONA House, Mondeal Business Park, Thaltej, Ahmedabad, Gujarat 380059
Phone: +91 79 4023 3000 | Email: complianceofficer@coronaremedies.com

Registrar: Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200 | Email: ipo@bigshareonline.com

Quick Review — Buy or Not?

Corona Remedies shows strong revenue growth, excellent margins, and a highly scalable distribution network. Being an OFS-only IPO, no funds go to the company. Valuations are on the higher side (35x P/E post-issue). Suitable for long-term pharma-focused investors wanting stable branded formulations exposure. Review RHP for detailed risks.

Not investment advice — for educational use only.

10 thoughts on “Corona Remedies IPO 2025 — Price Band, Dates, Lot Size, Financials & Review”

  1. Today, I went to the beachfront with my kids. I found a sea
    shell and gave it to my 4 year old daughter and said
    “You can hear the ocean if you put this to your ear.” She placed the shell to her ear and screamed.
    There was a hermit crab inside and it pinched her ear.
    She never wants to go back! LoL I know this is totally off topic but I had to tell someone!

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top